Page 56 - Pharmacy Appeals 1/4/04 to 31/3/05
P. 56
32 Performance analysis
Given these figures, maternity continues to be a central plank of our strategic focus as we transition
from our previous five-year strategy (spanning 2017 to 2022) to a new three-year strategy (2022
to 2025). We remain committed to the aim of our previous strategy to 'provide analysis and
expert knowledge to the healthcare and civil justice systems, to drive improvement'.
Figure 4:
The number of maternity cerebral palsy/brain damage claims received over time across
all clinical negligence schemes1
300
Financial year
| Non-Early Notification Scheme case | Early Notification Scheme case
Figure 5:
The total value of maternity cerebral palsy/brain damage claims received overtime across
all clinical negligence schemes
3000
Financial year
| Non-Early Notification Scheme case | Early Notification Scheme case
The numbers of confirmed cerebral palsy/brain damaged baby claims will not directly align with the number
of EN cases, as the baby may be too young to diagnose at the point of becoming an EN case and indeed
incidents of potential harm may not ultimately translate into clinical negligence cases.
